Kendell D. Peterson

Kendell D. Peterson

Auto-generated profile, based on publicly available information

Kendell D. Peterson

Department of Pediatrics, Medical University of South Carolina, Charleston, South Carolina

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 March 2023 in Cancer Research Communications
Verified
Journal Article
Open access
PDF file
SOShaaron Ochoa-Rios
Shaaron Ochoa-Rios
CBCalvin R.K. Blaschke
Calvin R.K. Blaschke
MWMengjun Wang
Mengjun Wang
KPKendell D. Peterson
Kendell D. Peterson
ADAndrew DelaCourt
Andrew DelaCourt
AMAnand Mehta
Anand Mehta
There is an urgent need for the identification of reliable prognostic biomarkers for patients with intrahepatic cholangiocarcinoma (iCCA) and alterations in N-glycosylation have demonstrated an immense potential to be used as diagnostic strategies for many cancers, including hepatocellular carcinoma (HCC). N-glycosylation is one of the most common post-translational modifications known to be altered based on the status of the cell. N-glycan structures on glycoproteins can be modified based on the addition or removal of specific N-glycan residues, some of which have been linked to liver diseases. However, little is known concerning the N-glycan alterations that are associated with iCCA. We characterized the N-glycan modifications quantitatively and qualitatively in three cohorts, consisting of two tissue cohorts: a discovery cohort (n = 104 cases) and a validation cohort (n = 75), and one independent serum cohort consisting of patients with iCCA, HCC, or benign chronic liver disease (n = 67). N-glycan analysis in situ was correlated to tumor regions annotated on histopathology and revealed that bisected fucosylated N-glycan structures were specific to iCCA tumor regions. These same N-glycan modifications were significantly upregulated in iCCA tissue and serum relative to HCC and bile duct disease, including primary sclerosing cholangitis (PSC) (P < 0.0001). N-glycan modifications identified in iCCA tissue and serum were used to generate an algorithm that could be used as a biomarker of iCCA. We demonstrate that this biomarker algorithm quadrupled the sensitivity (at 90% specificity) of iCCA detection as compared with carbohydrate antigen 19-9, the current “gold standard” biomarker of CCA.Significance: This work elucidates the N-glycan alterations that occur directly in iCCA tissue and utilizes this information to discover serum biomarkers that can be used for the noninvasive detection of iCCA.

4 April 2023
Verified
Other
Open access
SOShaaron Ochoa-Rios
Shaaron Ochoa-Rios
CBCalvin R.K. Blaschke
Calvin R.K. Blaschke
MWMengjun Wang
Mengjun Wang
KPKendell D. Peterson
Kendell D. Peterson
ADAndrew DelaCourt
Andrew DelaCourt
AMAnand Mehta
Anand Mehta
Relative intensity quantification of all N-glycans identified in serum (left row) and tissue (right row) analysis. Red font labeling for N-glycans follows the same trend between serum and tissue.

4 April 2023
Verified
Other
Open access
SOShaaron Ochoa-Rios
Shaaron Ochoa-Rios
CBCalvin R.K. Blaschke
Calvin R.K. Blaschke
MWMengjun Wang
Mengjun Wang
KPKendell D. Peterson
Kendell D. Peterson
ADAndrew DelaCourt
Andrew DelaCourt
AMAnand Mehta
Anand Mehta
There is an urgent need for the identification of reliable prognostic biomarkers for patients with intrahepatic cholangiocarcinoma (iCCA) and alterations in N-glycosylation have demonstrated an immense potential to be used as diagnostic strategies for many cancers, including hepatocellular carcinoma (HCC). N-glycosylation is one of the most common post-translational modifications known to be altered based on the status of the cell. N-glycan structures on glycoproteins can be modified based on the addition or removal of specific N-glycan residues, some of which have been linked to liver diseases. However, little is known concerning the N-glycan alterations that are associated with iCCA. We characterized the N-glycan modifications quantitatively and qualitatively in three cohorts, consisting of two tissue cohorts: a discovery cohort (n = 104 cases) and a validation cohort (n = 75), and one independent serum cohort consisting of patients with iCCA, HCC, or benign chronic liver disease (n = 67). N-glycan analysis in situ was correlated to tumor regions annotated on histopathology and revealed that bisected fucosylated N-glycan structures were specific to iCCA tumor regions. These same N-glycan modifications were significantly upregulated in iCCA tissue and serum relative to HCC and bile duct disease, including primary sclerosing cholangitis (PSC) (P < 0.0001). N-glycan modifications identified in iCCA tissue and serum were used to generate an algorithm that could be used as a biomarker of iCCA. We demonstrate that this biomarker algorithm quadrupled the sensitivity (at 90% specificity) of iCCA detection as compared with carbohydrate antigen 19-9, the current “gold standard” biomarker of CCA.Significance:This work elucidates the N-glycan alterations that occur directly in iCCA tissue and utilizes this information to discover serum biomarkers that can be used for the noninvasive detection of iCCA.

4 April 2023
Verified
Other
Open access
SOShaaron Ochoa-Rios
Shaaron Ochoa-Rios
CBCalvin R.K. Blaschke
Calvin R.K. Blaschke
MWMengjun Wang
Mengjun Wang
KPKendell D. Peterson
Kendell D. Peterson
ADAndrew DelaCourt
Andrew DelaCourt
AMAnand Mehta
Anand Mehta
Peak list of N-glycans detected in tissue (TMA) and serum samples.

4 April 2023
Verified
Other
Open access
SOShaaron Ochoa-Rios
Shaaron Ochoa-Rios
CBCalvin R.K. Blaschke
Calvin R.K. Blaschke
MWMengjun Wang
Mengjun Wang
KPKendell D. Peterson
Kendell D. Peterson
ADAndrew DelaCourt
Andrew DelaCourt
AMAnand Mehta
Anand Mehta
Lists individual N-glycans, ALT (Alanine transaminase), AST (aspartate aminotransferase), ALK (Alkaline phosphatase), and AFP (Alpha-fetoprotein) of analysis to differentiate patients with iCCA from PSC. 1Possible biomarkers 2n: number of total patients 3distribution of iCCA (n=30) and PSC (n=17) patients. 4AUC (Area Under the Curve) 5CI (confidence interval) 6p value. Some iCCA patients were excluded from the analysis due to missing clinical information.

4 April 2023
Verified
Other
Open access
SOShaaron Ochoa-Rios
Shaaron Ochoa-Rios
CBCalvin R.K. Blaschke
Calvin R.K. Blaschke
MWMengjun Wang
Mengjun Wang
KPKendell D. Peterson
Kendell D. Peterson
ADAndrew DelaCourt
Andrew DelaCourt
AMAnand Mehta
Anand Mehta
Hematoxylin & Eosin (H&E) staining of A. Intrahepatic Cholangiocarcinoma (iCCA) tissue, 10x (right) and 40x (left) magnification images from respective areas of the tissue, and B. Hepatocellular Carcinoma (HCC) tissue, 10x magnification images from respective areas of the tissue. Tumor regions are outlined in red, normal areas are outlined in black and fibrotic regions are outlined in blue. C. TMA H&E staining with an outline that specifies the diagnosis for each core for TMA 1 (left) and TMA 2 (right). Mixed carcinoma: HCC and iCCA. Small (yellow) and large (purple) ducts classifications for each TMA.